Sage is attending BioEurope 2026
9-11 November in Cologne and would be pleased to meet you!
Specialist advice in licensing, partnering and M&A.
Turning life science innovation into opportunity
Sage helps biotechnology, pharmaceutical, regenerative medicine and health technology companies secure strategic licensing and development partners, complete strategic M&A and unlock asset value worldwide. Our Directors combine deep sector expertise, financial acumen, global relationships and SAGEIQ-enabled market intelligence to identify the right counterparties and guide transactions from strategy to completion.
Who we work with
Pharma, Biotech, MedTech, Regenerative Medicine and Diagnostics companies — licensing, development partnerships and strategic exits. Pharmaceutical and strategic buyers — focused sourcing of innovation and M&A opportunities. Investors and owners — structured partnering and sale processes to realise value.
Why choose Sage Healthcare
More than 30 years of life sciences deal-making experience, an international network and senior deal leadership from strategy through closing. SAGEIQ-enabled marketing intelligence helps us identify and prioritise relevant partners with precision, while our lead Directors help to shape the transaction, develop evaluation metrics, manage the process through from non-binding term sheets to a closed definitive agreement.
Selected transaction experience
Recent work includes advising PolyPid on its US and Canadian partnership with Azurity Pharmaceuticals for D-PLEX100, Hatchtech on the acquisition of Xeglyze by Pelthos Therapeutics, and Fabre-Kramer on its partnering agreement with Aytu BioPharma for EXXUA.
See the latest Sage news below for transaction announcements and explore About Sage for our platform, process and international expertise.
Sectors of expertise
We support pharmaceutical, biotechnology, regenerative medicine, medtech and diagnostics companies, alongside venture capital, private equity and strategic investors.
